ABINGWORTH
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
ABINGWORTH
Industry:
Biotechnology Health Diagnostics Medical Medical Device
Founded:
1973-01-01
Status:
Active
Contact:
(207) 534-1500
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Domain Not Resolving Mobile Non Scaleable Content Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Exabone
Exabone GmbH is a Swiss biotechnology leader strategically based within the fast growing life science cluster of Western Switzerland.
Nara Capital
Nara is a purpose-driven investment firm that invests in biotech & life sciences SMEs and startups.
RA Capital Management
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Xip
Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Advisor
Advisor
Current Employees Featured
Tim Haines Chairman and Managing Partner @ Abingworth
Chairman and Managing Partner
2019-09-01
Kurt von Emster Managing Partner @ Abingworth
Managing Partner
2015-01-01
James Abell Partner and CFO @ Abingworth
Partner and CFO
Alex Asquith General Counsel and Chief Financial Officer @ Abingworth
General Counsel and Chief Financial Officer
David Leathers Special Partner @ Abingworth
Special Partner
Shelley Chu Partner @ Abingworth
Partner
2015-10-19
Vincent Miles Partner @ Abingworth
Partner
Andrew Sinclair Partner & Portfolio Manager @ Abingworth
Partner & Portfolio Manager
Anthony Montagu Founder @ Abingworth
Founder
Peter Dicks Founder @ Abingworth
Founder
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-04-04 | Venatorx Pharmaceuticals | Abingworth investment in Series C - Venatorx Pharmaceuticals | 34 M USD |
| 2021-09-27 | Jasper Therapeutics | Abingworth investment in Post-IPO Equity - Jasper Therapeutics | 100 M USD |
| 2021-09-15 | Anjarium Biosciences | Abingworth investment in Series A - Anjarium Biosciences | 55.5 M CHF |
| 2021-09-08 | HilleVax | Abingworth investment in Venture Round - HilleVax | 135 M USD |
| 2021-08-26 | Effector Therapeutics | Abingworth investment in Post-IPO Equity - Effector Therapeutics | 60 M USD |
| 2021-08-02 | CymaBay Therapeutics | Abingworth investment in Post-IPO Debt - CymaBay Therapeutics | 100 M USD |
| 2021-07-15 | Wugen | Abingworth investment in Series B - Wugen | 172 M USD |
| 2021-06-23 | Glycomine | Abingworth investment in Series B - Glycomine | 35 M USD |
| 2021-04-19 | Adaptate Biotherapeutics | Abingworth investment in Series A - Adaptate Biotherapeutics | 13 M GBP |
| 2021-03-19 | X4 Pharmaceuticals | Abingworth investment in Post-IPO Equity - X4 Pharmaceuticals | 55 M USD |
Newest Events participated
Participated in The 2014 New England Venture Summit
on 2014-12-10 as sponsor
More informations about "Abingworth"
Abingworth (company) - Wikipedia
Abingworth LLP (formerly Abingworth Management Ltd.) is a transatlantic bioscience investment firm founded in 1973 by a pair of London stockbrokers, Peter Dicks and Hon. Anthony Montagu. Abingworth had initially sought to extend its investments into the biotechnology industry in the late 1980s, and has subsequently been investing in life science and healthcare services companie…See details»
About - Abingworth LLP
Abingworth has raised 15 funds dedicated to investing in life sciences and healthcare. Our most recent venture fund, Abingworth Bioventures 8, raised $466 million while Abingworth’s Clinical Co-Development Fund 2 and Clinical Co …See details»
Carlyle Completes Acquisition of Abingworth and Announces Go …
Aug 3, 2022 NEW YORK, NY – Global investment firm Carlyle (NASDAQ: CG) and Abingworth, a transatlantic life sciences investment firm with approximately $2 billion in assets under …See details»
Abingworth - Crunchbase Investor Profile & Investments
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, …See details»
We are delighted to announce that Abingworth LLP will become …
Apr 11, 2022 Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. www.abingworth.com. …See details»
Carlyle's acquisition of Abingworth brings $2 billion to fuel life ...
Apr 12, 2022 Carlyle’s acquisition of Abingworth, announced Monday, was short on details but high on 10-figure-plus chest puffing. Carlyle, an investment firm with more than $301 billion in …See details»
Abingworth - LinkedIn
Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has ...See details»
Abingworth raises $356 million for new Clinical Co-Development …
Oct 30, 2023 Abingworth extends its capital base for late-stage clinical programs with pharma and biotech partners London, UK and New York, USA, October 30, 2023 - Abingworth, a …See details»
Abingworth raises $465M fund, steps up interest in …
Feb 3, 2021 Abingworth has raised a $465 million life sciences fund, positioning it to build on earlier investments in biotechs including Alnylam and CRISPR Therapeutics. The transatlantic fund will follow a ...See details»
Abingworth Company Profile - Office Locations, Competitors
Abingworth is an international bioscience investment firm that invests in seed stage projects, technology platforms, preclinical and clinical assets, and approved and marketed products. Its …See details»
Abingworth raises $356M to invest in late-stage drug development
Oct 30, 2023 Abingworth exceeded its own targets with its most recent capital raise. The firm initially sought $300 million for its Clinical Co-Development Co-Investment Fund, which was …See details»
Abingworth - Investments, Portfolio & Company Exits - Crunchbase
Abingworth 's most notable exits include Vera Therapeutics, ... Which industries has this organization had the most exits in? Show . Vera Therapeutics Vera Therapeutics is a …See details»
Our Strategy - Abingworth LLP
Venture; CCD; Typical Investment Size $15-$30mIn total per company Geography Primarily US & Europe Holding Period 3-8 years Sectors. Biotherapeutics, small molecules, nucleic acid …See details»
List of top Abingworth Portfolio Companies - Crunchbase
May 27, 2004 Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs. This list of organizations invested in by Abingworth provides data on …See details»
Abingworth investment portfolio - PitchBook
Founded in 1973, Abingworth is a venture capital firm based in London, United Kingdom. The firm prefers to invest in seed-stage, early-stage, growth-stage, and later-stage companies. The firm …See details»
Abingworth raises $465m for new life sciences venture fund
Feb 3, 2021 Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top …See details»
Abingworth raises $465m for new life sciences fund Abingworth …
LONDON, Feb. 3, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its latest transatlantic venture fund, …See details»
Abingworth raises $582 million for new Clinical Co-Development …
LONDON, May 10, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its new Clinical Co-Development Fund …See details»
The Carlyle Group acquires Abingworth - 2022-04-11 - Crunchbase
Apr 11, 2022 Abingworth Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs. Acquiring Organization: The Carlyle Group The …See details»